FRANKFURT, Feb 7 (Reuters) - The European Union's drugs regulator said on Wednesday it will assess the impact on the availability of medicines processed at Catalent sites that will be sold to Novo Nordisk. (Reporting by Ludwig Burger)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
55.92 USD | -0.12% | -1.13% | +24.33% |
05-09 | MOVES -Lazard hires veteran healthcare dealmaker Colocci as vice chairman | RE |
05-08 | Earnings Flash (CTLT) CATALENT Posts Q3 Revenue $1.07B | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
883.2 DKK | +0.07% | +1.16% | 568B | ||
762.1 USD | -1.22% | +3.61% | 695B | ||
55.92 USD | -0.12% | -1.13% | 10.13B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.33% | 10.13B | |
+30.63% | 695B | |
+26.51% | 568B | |
-4.63% | 361B | |
+19.57% | 330B | |
+3.79% | 283B | |
+16.70% | 239B | |
+8.78% | 204B | |
-7.93% | 198B | |
+7.90% | 168B |
- Stock Market
- Equities
- CTLT Stock
- News Catalent, Inc.
- EU watchdog to assess availability of drugs made at Catalent sites sold to Novo